NYSE · Drug Manufacturers - Specialty & Generic · USD
Elanco Animal Health Incorporated (ELAN) Stock Analysis
Elanco Animal Health Incorporated (ELAN) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ELAN Key Statistics
As of Sep 4, 2026Trading
- Open
- $24.20
- Previous Close
- $24.42
- Day's Range
- 24.00–24.71
- 52-Week Range
- 18.22–27.98
- Volume
- 3.72M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.68
Valuation
- Market Cap
- $12.24B
- P/E Ratio
- unprofitable
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 19.15
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 4.04
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 2.44
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.41
Financials (FY)
- Revenue (FY)
- $4.72B+6.22%
- Net Income (FY)
- −$232.00M−168.64%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −3.96%
- Shares Outstanding
- 499.45M
- 1-Year Return
- +40.24%
Dividend and dates
- Earnings Date
- November 5, 2026estimated
- Avg Volume
- 6.03M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
ELAN Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +8.26% |
| 2025 | +86.87% |
| 2024 | −18.72% |
| 2023 | +21.93% |
| 2022 | −56.94% |
| 2021 | −7.47% |
| 2020 | +4.14% |
| 2019 | −6.60% |
| 2018 (partial year) | −12.42% |
As of September 4, 2026.
ELAN Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $4.72B | −$232.00M | −4.9% |
| 2024 | $4.44B | $338.00M | 7.6% |
| 2023 | $4.42B | −$1.23B | −27.9% |
| 2022 | $4.41B | −$78.00M | −1.8% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $4.72B | $2.59B | $252.00M | −$232.00M | −4.9% |
| 2024 | $4.44B | $2.44B | $251.00M | $338.00M | 7.6% |
| 2023 | $4.42B | $2.49B | $326.00M | −$1.23B | −27.9% |
| 2022 | $4.41B | $2.50B | $384.00M | −$78.00M | −1.8% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
ELAN Valuation vs Drug Manufacturers - Specialty & Generic Median
Median of 103 stocks| Metric | ELAN | Drug Manufacturers - Specialty & Generic median | vs median |
|---|---|---|---|
| P/S ratio | 2.44 | 2.30 | 6% above |
| Profit margin | −3.96% | −3.14% | 0.8 pts below |
Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Elanco Director Purchases 40,000 Shares for $936,000
YahooElanco Scales Biologics Capabilities With Expansion of Kansas Manufacturing Facility
YahooElanco celebrates $120 million expansion of Elwood manufacturing facility
YahooElanco Animal Health Announces On-Time Completion Of 25K-Square-Foot Manufacturing Expansion Of Its Elwood, Kansas Manufacturing Site
BenzingaElanco Animal Health: New Products To Support Growth
SeekingAlphaDirector's Confidence Visible as Elanco Leader Buys 10,000 Shares
Yahoo
All 20 articles ↓Show fewer ↑
Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC’s ‘Final Trades’
Benzinga5 Must-Read Analyst Questions From Elanco’s Q2 Earnings Call
YahooElanco (ELAN) Q2 2026 Earnings Call Transcript
YahooElanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform
SeekingAlphaElanco's CLiK(TM) Extra (Dicyclanil Topical Suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
YahooDoes Elanco (ELAN) Have a Durable Edge in Animal Health After Its Screwworm EUA Win?
YahooElanco Animal Health (ELAN) Following FDA Emergency Use Authorization Has Valuation Back In Focus
YahooElanco Animal Health Q2 Earnings Call Highlights
YahooElanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
YahooReported Earlier, FDA Issues Issues Emergency Use Authorization For Elanco's CLiK Extra Wound Spray For Prevention Of New World Screwworm Infestations
BenzingaElanco CEO on Boosted Forecast, Surge in Tick Bites
YahooADUS vs. ELAN: Which Stock Is the Better Value Option?
YahooUBS Maintains Buy on Elanco Animal Health, Raises Price Target to $33
BenzingaKeybanc Maintains Overweight on Elanco Animal Health, Raises Price Target to $30
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Drug Manufacturers - Specialty & Generic Stocks
Takeda Pharmaceutical Company Limited
$58.92B
TEVATeva Pharmaceutical Industries Limited
$42.37B
HLNHaleon plc
$42.22B
ZTSZoetis Inc.
$31.33B
UTHRUnited Therapeutics Corporation
$20.91B
VTRSViatris Inc.
$19.39B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B